Health
Rapid generation of divergent synthetic antibodies against SARS-CoV-2 in a cell-free engineering platform – News-Medical.Net
In a groundbreaking bioRxiv paper, a research group from the Massachusetts Institute of Technology (MIT), Harvard University and Howard Hughes Medical Institute…
In a groundbreaking bioRxiv* paper, a research group from the Massachusetts Institute of Technology (MIT), Harvard University and Howard Hughes Medical Institute in the US engineered antibodies against the receptor-binding domain (RBD) of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike glycoprotein by using a novel approach. In doing so, they also identified more than 800 predicted binder families.
The ongoing coronavirus disease (COVID-19) pandemic is caused by the SARS-CoV-2,…
-
Noosa News24 hours agoInside the final hours before Australian lawyer Christopher Saines died in Thai massage parlour
-
General22 hours agoGerman backpacker Carolina Wilga found alive in WA’s outback
-
General11 hours agoThailand punches above its weight in film creativity and cross-border appeal. Here’s why
-
Business24 hours agoHow $1,000 a month in this ASX ETF could turn into $500,000